Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOXIL and Docetaxel vs Docetaxel in Advanced Breast Cancer
NCT00091442Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Sep 2004
- Primary completion
- Dec 2008
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of doxorubicin liposomal in breast cancer (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Time to Progression at 15 months. Started Sep 2004; status: completed.
02
Drugs
doxorubicin liposomal
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00091442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00091442.